The purpose of this phase II study was to evaluate the feasibility of hypofractionated radiotherapy (HFRT) with a dose of in 10 fractions in postmastectomy patients. From March 2014 to December 2015, 85 patients with locally advanced breast cancer were eligible to participate in this study with a schedule of in 10 fractions. | Jiang et al. BMC Cancer 2021 21 1284 https s12885-021-09032-8 RESEARCH Open Access Hypofractionated radiotherapy in ten fractions for postmastectomy patients a phase II study compared with another hypofractionation schedule with sixteen fractions Huayong Jiang1 2 Lingling Meng2 Huijuan Zhang2 Xiangkun Dai2 Qian Zhang2 Zhongjian Ju2 Wei Yu2 and Lin Ma1 2 Abstract Background The purpose of this phase II study was to evaluate the feasibility of hypofractionated radiotherapy HFRT with a dose of Gy in 10 fractions in postmastectomy patients. Methods From March 2014 to December 2015 85 patients with locally advanced breast cancer were eligible to participate in this study with a schedule of Gy in 10 fractions. Intensity-modulated radiation therapy IMRT was delivered to the chest wall with or without the supraclavicular region. The primary endpoint was radiation-related toxicities. The secondary endpoints were locoregional failure-free survival LRFFS disease-free survival DFS and overall survival OS . And the outcomes were compared with our retrospective study of 72 patients with Gy in 16 fractions. Results The median follow-up was range months in the Gy group and range months in the Gy group respectively. Radiation-related toxicities were mainly grade 1 although a few patients had grade 2 plexopathy and acute skin toxicity in the Gy group and grade 2 acute skin toxicity and lymphedema in the Gy group. There were no significant differences between the groups in acute and late toxicities. For all the patients the 5-year LRFFS DFS and OS were and and and respectively without significant differences between the groups. Conclusion Postmastectomy HFRT with a schedule of Gy in 10 fractions was feasible with mild toxicities and excellent 5-year clinical outcome. Trial registration Trial registration number ChiCTR- ONRC- 14004 391. Date of .
